An Oct. 13 research note indicated the U.S. Food and Drug Administration (FDA) accepted ProMetic Life Sciences Inc.'s (PLI:TSX) biologics license application for Ryplazim (plasminogen) and set a PDUFA date of April 14, 2018.
"We view this to be an important milestone for the company (removing a significant overhang for the stock), as it provides certainty in a process that has been anything but," noted Neil Maruoka, an analyst with Canaccord Genuity. "With an FDA decision date now in hand, we believe that ProMetic now has a clearer pathway to a potential approval of its first major therapeutic."
Maruoka expressed optimism regarding ProMetic's biologic. "We believe the drug could address an unmet clinical need, and we see a strong likelihood that Ryplazim will be approved next year, providing a significant potential catalyst for the stock." In its favor are "strong clinical data, orphan drug status, an accelerated approval pathway and a rare pediatric disease designation."
The FDA also afforded ProMetric "a priority review (and an 'official' six-month review period), and we believe the company is therefore eligible to receive a priority review voucher (PRV) if Ryplazim is approved," Maruoka wrote. "We believe this would be a valuable asset for ProMetic." Such a voucher decreases the review period for a drug to six months from ten. It is "transferable, and PRVs have been sold in the past for over $100M."
In the research report, Maruoka identified cash burn as "the key risk for ProMetic," which he would like to see reduced ahead of the FDA ruling next year.
Along with the anticipated FDA approval of Ryplazim, other short-term catalysts for the company are "more data from PBI-4050" and "the initiation of clinical studies for PBI-4050 in idiopathic pulmonary fibrosis and diabetic kidney disease," the analyst noted.
On ProMetic, Canaccord Genuity has a CA$4.25 per share price target, which, Maruoka explained, "implies a 172% annualized return and continues to support our Buy recommendation." The biotech's stock is currently trading at around CA$1.59 per share.
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
Disclosures from Canaccord Genuity, ProMetic Life Sciences, Oct. 13, 2017
Analyst Certification: Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst’s personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst’s coverage universe and (ii) no part of the authoring analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research.
Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity Inc. and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.
Canaccord Genuity or one or more of its affiliated companies intend to seek or expect to receive compensation for Investment Banking services from ProMetic Life Sciences Inc. in the next three months.
Up-to-date disclosures may be obtained here.